Skip To Content
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Before it's here, it's on the Bloomberg Terminal.
Learn More
067080:KSKOSDAQ

Dae Hwa Pharmaceutical Co Ltd

COMPANY INFO
14,650.00KRW
+150.00+1.03%
Market Closed
As of 02:59 AM EDT 09/25/2020 EDT
Open
14,550.00
Prev Close
14,500.00
Volume
243,654
Market Cap
271.349B
Day Range
14,400.0015,200.00
52 Week Range
5,820.0023,000.00
1D1M1Y5Y
View Full Chart
Market Closed
As of 02:59 AM EDT 09/25/2020 EDT
1D1M1Y5Y
View Full Chart
markets
Covid-19 Restrictions Renewed Across Europe as Cases Surge
Before it's here, it's on the Bloomberg Terminal.
Learn More
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Key Statistics

P/E Ratio44.09
PEGY Ratio--
Shares Outstanding18.52M
Price to Book Ratio3.2331
Price to Sales Ratio2.2705
1 Year Return17.20%
30 Day Avg Volume1,827,031
EPS332.25
Dividend1.02%
Last Dividend Reported50
Earnings Announcement for Period Ending Q3/2020:11/16/2020

Compare
1-Day Performance

0+2%
0+2%
Equity
067080:KS
+1.03%
Sponsored By

About Dae Hwa Pharmaceutical Co Ltd

Dae Hwa Pharmaceutical Co., Ltd. develops and manufactures a variety of pharmaceutical drugs, such as analgesics and anti-inflammatory drugs, antihistamines, skeletal muscle relaxants, and cardiovascular drugs.
Address
495 Hanu-ro Hoengseong-eup Hoengseon-gun Gangwon Korea, Republic of (South)
Phone
82-2-586-6451
Website
www.dhpharm.co.kr

Income Statement

Quarterly
Annual
;
Q2 2020 (Millions KRW)
  • Revenue
    26,774.29
  • Net Income
    -1,028.10
  • Profit Margin
    -3.84%

Balance Sheet

Quarterly
Annual
;
Q2 2020 (Millions KRW)
  • Total Assets
    173,054.96
  • Total Liabilities
    90,849.19
  • Debt to Assets
    35.54%

Cash Flow

Quarterly
Annual
Q2 2020 (Millions KRW)
  • Operating
    -1,452.68
  • Investing
    -3,514.18
  • Financing
    6,517.07